Abstract
Purpose
Genes and pathways involved in early growth plate chondrocyte recovery after fractionated irradiation were sought as potential targets for selective radiorecovery modulation.
Methods and Materials
Three groups of six 5 week male SD rats underwent fractionated irradiation to the right tibiae over 5 days totaling 17.5 Gy and then were killed at 7, 11 and 16 days following the first radiotherapy fraction. The growth plates were collected from the proximal tibiae bilaterally and subsequently underwent laser microdissection to separate reserve, perichondral, proliferative, and hypertrophic zones. Differential gene expression was analyzed between irradiated right and non-irradiated left tibia using RAE230 2.0 GeneChip microarray, compared between zones and time points and subjected to functional pathway cluster analysis with real-time PCR to confirm selected results.
Results
Each zone had a number of pathways showing enrichment following the pattern of hypothesized importance to growth plate recovery, yet few met the strictest criteria. The proliferative and hypertrophic zones showed both the greatest number of genes with a 10 fold right/left change at 7 days after initiation of irradiation and enrichment of the most functional pathways involved in bone, cartilage, matrix and/or skeletal development. Six genes confirmed by real-time PCR to have early upregulation included Igf2, Col1a2, Mmp9, Pthr1, Fmod, and Agc1.
Conclusions
Nine overlapping pathways in the proliferative and hypertrophic zones (skeletal development, ossification, bone remodeling, cartilage development, extracellular matrix structural constituent, proteinaceous extracellular matrix, collagen, extracellular matrix, and extracellular matrix part) may play key roles in early growth plate radiorecovery.
Keywords: Growth plate, microarray, chondrocytes, rat, irradiation
Introduction
Longitudinal bone growth results from orderly coordination of chondrocyte proliferation and hypertrophy, calcification of the matrix, vascular invasion, and completion of endochondral bone formation in the growth plate. Despite recent advances, a complete understanding of the factors regulating progression in the growth plate has not been achieved. Even less is understood about the mechanisms of recovery of the growth plate from radiation damage. What is known is that children who receive radiotherapy for bone or soft-tissue sarcomas in areas close to a growth plate are at high risk for developing growth arrest, angular deformity, and/or limb length discrepancy. (1,2,3)
Some capacity for growth plate recovery after irradiation appears to exist, based both on the variability of clinical outcomes following irradiation of the growth plate and on evidence from our own work in the weanling Sprague-Dawley rat model. Our recent work has focused on obtaining a better understanding of early growth plate recovery in order to develop potential selective radiorecovery agents for clinical use during radiotherapy treatment of pediatric solid tumors. It is postulated that identification of key early upregulated genes may provide an understanding of the mechanism of this recovery and lend itself to the development of novel radiorecovery agents.
In our earlier work a single fraction model was utilized for simplicity’s sake. (4,5) Examination of gene recovery isolated to the proliferative (PZ) and hypertrophic (HZ) zones suggested a specific pattern of radiorecovery involving phased upregulation of both matrix elements and growth factors/cytokines. Since fractionation is the clinical norm; we sought in this manuscript to report the more clinically relevant pattern of radiorecovery following fractionated irradiation. In addition, since key growth plate regulatory elements are thought to be generated in the perichondrium and reserve zone, these zones were also isolated by laser microdissection in the current report.
The purpose of this report was to utilize laser microdissection and microarray to separate and characterize gene expression in four zones of the growth plate after fractionated irradiation, as well as to determine enrichment of gene ontology functional groups in significantly changed genes. Our hypothesis was that differential upregulation of specific gene expression exists between irradiated and nonirradiated reserve zone (RZ), proliferative zone (PZ), perichondrium (PC) and hypertrophic zone (HZ) chondrocytes and that some factors potentially vital to growth plate recovery would follow a pattern of early upregulation followed by a decrease in expression.
Methods
All animal procedures were reviewed and approved by the Institutional Use and Care of Animals Committee (IUCAC). Three groups of six 5 week male SD rats underwent fractionated irradiation to the right tibiae over 5 days totaling 17.5 Gy. The left side tibiae served as non-irradiated controls. At 7, 11 and 16 days following the first radiotherapy fraction, the animals were killed by carbon-dioxide asphyxiation, and the growth plates were collected from the proximal tibiae bilaterally and immediately frozen in liquid nitrogen and stored at -70°C. The entire collecting process was completed within two minutes.
These timepoints were chosen based upon previous work showing that, from a histologic perspective, the growth plate reaches its most disorganized, paucicellular state at approximately one week after irradiation. Gradual recovery has been noted thereafter, with clones of regenerating chondrocytes clearly identified beginning at 2 weeks after irradiation. Hence, in order to find genes that might play a role in stimulating growth plate recovery, we hypothesized that the key genes would be upregulated by 7 days but would gradually return toward normal by 11 and 16 days after irradiation.
Laser Microdissection
Serial sections (6 μm for laser microdissection) were cut on a Leica CM3050 cryostat immediately before the planned laser microdissection. The laser microdissection (LMD), RNA extraction and Gene Chip Hybridization procedures were previously described.(6) For each of the four zones at each of the three time points, equal amounts of RNA from the three samples derived from three different limbs on each side (right and left) were pooled to create a single sample to reduce the individual variability and sampling errors, resulting in eight samples of RNA from the six limbs at each time point, 24 samples in all.(Figure I) The twenty-four RNA samples included the right RZ at 7 days, left RZ at 7 days, right PZ at 7 days, left PZ at 7 days, right HZ at 7 days, left HZ at 7 days, right PC at 7 days, and left PC at 7 days, and identical sets for 11 and 16 days. Each pooled sample had 30-50 ng RNA.
Figure 1.
Flow chart of experimental methods and sample organization for microarray analysis.
Real-Time RT-PCR
Real time quantitative RT-PCR was performed as previously described.(6) The 25 μl reaction consisted of SYBR Green PCR Master Mix (PE Applied Biosystems, CA), rat specific primers for genes Igf2, Col1a2, Mmp9, Pthr1, Fmod, Agc1 at a concentration of 300 nM, and 5 ng pooled cDNA. All samples were run in triplicate along with 18srRNA as reference gene (forward, 5′GGTCATAAGCTTGCGTTGAT3′, reverse, 5′TCAAGTTCGACCGTCTTCTC3′) and no template controls.
Analysis of Changes in Gene Expression
To identify differentially expressed genes in RZ, PZ, HZ and PC, RAE230 2.0 GeneChip microarray chips were used and Affymetrix GCOS/MAS 5 was used to generate a list of genes designated as “present” in any or all zones. Then, GeneSpring GX (Agilent Technologies,Palo Alto, CA) was used to identify differentially expressed genes in right zonal samples which were normalized to the left tibia at each of the three time points using the Robust Multiarray Analysis (RMA) method. An intensity filter of 10 times the lowest background expression level was applied in GeneSpring to normalized data in order to cut out very low expressed genes. Meaningful differential expression was determined at the 99.9% confidence level.(7) We included genes at the extreme tails of the distribution curve at +/- 3.3 z-scores from the mean, rather than an arbitrary fold difference.
Two additional steps were used for the microarray analysis: clustering self-organizing maps (SOM) and pathway analysis. Gene lists were clustered by SOM in GeneSpring, and clusters fitting the hypothesized temporal expression pattern (upregulation at 7 days, then decreasing expression at 11 and 16 days) were selected within each zone (RZ, PZ, HZ, and PC) for additional pathway analysis. Based on our hypothesis that the pattern of importance was limited to those genes that were significantly differentially expressed at 7 days on the irradiated side compared to the non-irradiated side and then decreased, we selected either a 4×3 or a 3×2 matrix depending upon the best fit of the data. For the RZ there were 23 genes that passed our expression level filter and for PC there were only 18 genes that passed the expression level filter, so a smaller (3×2) matrix sufficed. By contrast, for the PZ and HZ, with 244 and 245 genes passing the expression level filter, respectively, a 4×3 matrix did not adequately separate out a limited number of clusters that fit the desired pattern. Therefore, we discarded the SOM in lieu of simply analyzing these genes as one large group, for PZ and HZ separately, for the purposes of pathway analysis.
Functional pathway analysis for all zones was accomplished using hypergeometric p-values, manually performed in Microsoft Excel, to confirm significance, accepting hypergeometric p values of less than 0.05. In addition to the hypergeometric p-values, pathways also had to include >1 probe set from the experimental data set and to have a fold enrichment score (FER) ≥5 in order to be considered meaningful.
For all four growth plate zones (RZ, PZ, PC, HZ), overall pathway analysis of all genes that met the expression level filter was accomplished independent of their temporal expression pattern. As in the pathway analysis of the individual clusters, enrichment of GO functional groups was determined to be meaningful with the number of probe sets in our experimental data of >1, hypergeometric p-values of less than 0.05, and fold enrichment of ≥5. We also identified enriched GO groups that are involved in skeletal development and bone remodeling. The latter screen was determined based on a search utilizing AmiGO, a search engine for the GeneOntology database (http://amigo.geneontology.org/cgi-bin/amigo/go.cgi). The experimental series of data files has been deposited into the Gene Expression Omnibus (GEO) at NCBI (accession GSE9537).
Results
Of the 31,099 probe sets arrayed on the chips, 23 RZ genes, 244 PZ genes, 245 HZ genes, and 18 PC genes having differential expression within the previously defined parameters were selected for further analysis.
Reserve Zone
A 3×2 SOM was performed to cluster RZ genes, and three of the six clusters showed progressive upregulation from 7 to 11 to 16 days.(Supplementary Fig 1) Two clusters (1,2) and (1,3) fit the pattern of significant upregulation on day 7 with expression decreasing on days 11 and 16.(Supplementary Fig 1) On pathway analysis of this cluster, no significant enrichment of GO groups was determined. Cluster (1,3) comprised 6 genes of which 4 were significantly upregulated at seven days.(Table I)
Table I.
Fold changes of irradiated RZ chondrocytes normalized to non-irradiated RZ chondrocytes over time from cluster (1,3). Red indicates significantly upregulated fold changes while green indicates significantly downregulated fold changes
Differential Expression of RZ genes in Cluster (1,3) | |||||||
---|---|---|---|---|---|---|---|
99.9% CI | |||||||
Log2 ratio (R/L) | |||||||
7d | 11d | 16d | |||||
Mean Log2 | 0.00 | 0.01 | 0.01 | ||||
StDev | 0.75 | 0.44 | 0.72 | ||||
+99.9 CL | 2.53 | 1.49 | 2.44 | ||||
# Incr 99.9CL | 73 | 119 | 315 | ||||
-99.9 CL | -2.53 | -1.47 | -2.41 | ||||
# Decr 99.9CL | 371 | 280 | 93 | ||||
Log2 ratio (R/L) | Fold Change | ||||||
Systematic Name | Gene Title | Gene Symbol | 7days | 11days | 16days | 7days | 11days |
1393160_at | Transcribed locus, weakly similar to NP_035665.2 T-box 3 protein isoform 1 [Mus musculus] | --- | 3.68 | 0.44 | 0.16 | 12.83 | 1.36 |
1377558_at | Cell division cycle 25 homolog A (S. cerevisiae) | Cdc25a | 3.68 | 0.48 | -0.73 | 12.80 | 1.39 |
1376938_at | Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform | Ppp2r2a | 3.62 | -0.44 | -0.55 | 12.28 | -1.35 |
1380747_at | Pre-B-cell leukemia transcription factor 1 (predicted) | Pbx1_predicted | 3.48 | 0.84 | 0.07 | 11.16 | 1.80 |
1368655_at | proteoglycan peptide core protein | Pgsg | 2.29 | -3.25 | -3.31 | 4.89 | -9.52 |
1377998_at | coproporphyrinogen oxidase | Cpox | 1.07 | -3.57 | -0.96 | 2.11 | -11.92 |
Falls within +99.9% CI | Fold Change | ||||||
Falls within -99.9% CI | Fold Change |
On pathway analysis of the entire group of 23 RZ genes meeting the differential expression level filters, enrichment was seen for 16 GO ontology pathways, including 4 molecular and 12 biological but no cellular pathways. Hence, these represent enriched RZ pathways containing genes differentially expressed at some point during the period after irradiation, but not necessarily following the hypothesized time pattern. Of these, there were no pathways specifically involving BCMSD. (Table II) None of these 16 pathways had five or more probe sets in our experimental data.(Table III)
Table II.
RZ enriched pathways from the cluster analysis showing hypergeometric p values less than 0.05. These pathways were derived from the only RZ cluster showing differential upregulation at 7 days (compared to non-irradiated chondrocytes) followed by a decrease at 11 and 16 days
RZ Enriched Pathways after Differential Expression Analysis of 23 Genes in Gene List | |||||||||
---|---|---|---|---|---|---|---|---|---|
GO Parent Category | GO Term | GO (Child) Term | GO ID | % of Array | % of list | Fold Enrichment | P value | Total Probe Sets On Array | Probe Sets in Your List |
Biological Process | Biological Regulation | positive regulation of cell proliferation | 8284 | 1.16% | 8.70% | 7.49 | 0.026658 | 360 | 2 |
Cell Cycle | mitosis | 7067 | 0.65% | 8.70% | 13.48 | 0.009159 | 200 | 2 | |
M phase of mitotic cell cycle | 87 | 0.65% | 8.70% | 13.28 | 0.009417 | 203 | 2 | ||
M phase | 279 | 0.84% | 8.70% | 10.37 | 0.014874 | 260 | 2 | ||
mitotic cell cycle | 278 | 1.14% | 8.70% | 7.64 | 0.025753 | 353 | 2 | ||
cell cycle phase | 22403 | 1.19% | 8.70% | 7.29 | 0.027969 | 370 | 2 | ||
Cellular Process | protein amino acid dephosphorylation | 6470 | 0.60% | 8.70% | 14.49 | 0.007994 | 186 | 2 | |
cellular morphogenesis during differentiation | 904 | 1.14% | 8.70% | 7.64 | 0.025753 | 353 | 2 | ||
cell proliferation | 8283 | 3.33% | 17.39% | 5.23 | 0.005678 | 1031 | 4 | ||
Metabolic Process | dephosphorylation | 16311 | 0.67% | 8.70% | 13.02 | 0.009766 | 207 | 2 | |
Multicellular Organismal Process | sensory perception | 7600 | 1.20% | 8.70% | 7.27 | 0.028102 | 371 | 2 | |
Response to Stimulus | response to drug | 42493 | 0.69% | 8.70% | 12.66 | 0.010299 | 213 | 2 | |
Molecular Function | Catalytic Activity | phosphoprotein phosphatase activity | 4721 | 0.69% | 8.70% | 12.54 | 0.010480 | 215 | 2 |
phosphoric monoester hydrolase activity | 16791 | 1.09% | 8.70% | 8.00 | 0.023727 | 337 | 2 | ||
phosphoric ester hydrolase activity | 42578 | 1.40% | 8.70% | 6.21 | 0.036843 | 434 | 2 | ||
Enzyme Regulator Activity | GTPase regulator activity | 30695 | 1.42% | 8.70% | 6.13 | 0.037714 | 440 | 2 |
Table III.
Enriched pathways (independent of time course) related to bone, cartilage, matrix and/or skeletal development (BCMSD) comprised of 5 or more probe sets from our data and their corresponding zones
Ontologies associated with Bone, Cartilage, Matrix and Skeletal Development with 5 or more probe sets form our data | |||||||||
---|---|---|---|---|---|---|---|---|---|
GO Term Associations | |||||||||
Go ID | GO Term | Skeletal Development | Bone Remodeling | Bone Mineralization | Extracellular matrix | Extracellular matrix structural constituent | Cartilage development | GP Zone | |
1501 | skeletal development | √ | PZ | HZ | |||||
1503 | ossification | √ | √ | PZ | HZ | ||||
5201 | extracellular matrix structural constituent | √ | PZ | HZ | |||||
5578 | proteinaceous extracellular matrix | √ | PZ | HZ | |||||
5581 | collagen | √ | PZ | HZ | |||||
5604 | basement membrane | √ | HZ | ||||||
30282 | bone mineralization | √ | √ | √ | HZ | ||||
31012 | extracellular matrix | √ | PZ | HZ | |||||
44420 | extracellular matrix part | √ | PZ | HZ | |||||
45453 | bone resorption | √ | √ | HZ | |||||
46849 | bone remodeling | √ | √ | PZ | HZ | ||||
51216 | cartilage development | √ | √ | PZ | HZ |
Proliferative Zone
For the PZ genes, both 3×2 and 4×3 SOM’s were examined in cluster analysis, and all but one cluster followed to some extent the hypothesized pattern.(Supplementary Fig 2) Therefore, pathway analysis of the entire group of 244 genes passing the differential expression level filter was done in lieu of detailed cluster analysis.(Table IV) This showed 103 enriched pathways with a minimum of 2 probe sets and a minimum fold enrichment of 5. These pathways included 32 molecular, 28 cellular, and 43 biological pathways. Sixteen pathways (16%) involved BCMSD.(Table III) Forty-three of the 103 (42%) pathways had a minimum of five probe sets in our data set. Nine (9%) of those 103 pathways involved BCMSD and also had a minimum five probe sets in our data set.(Table III)
Table IV.
PZ 103 enriched pathways from the cluster analysis showing hypergeometric p values less than 0.05. These pathways were derived from the entire PZ gene list showing differential upregulation at 7 days (compared to non-irradiated chondrocytes) followed by a decrease at 11 and 16 days. Gray indicates a pathways association with BCMSD
PZ Enriched Pathways after Differential Expression Analysis of 244 Genes in Gene List | |||||||||
---|---|---|---|---|---|---|---|---|---|
GO Parent Category | GO Term | GO (Child) Term | GO ID | % of Array | % of list | Fold Enrichment | P value | Total Probe Sets On Array | Probe Sets in Your List |
Biological Process | Biological Regulation/Cellular Process | iron ion homeostasis | 6879 | 0.11% | 1.23% | 11.55 | 0.002079 | 33 | 3 |
transition metal ion homeostasis | 46916 | 0.18% | 1.64% | 9.07 | 0.000918 | 56 | 4 | ||
Biological Regulation/Multicellular Organismal Process | regulation of sensory perception of pain | 51930 | 0.03% | 0.82% | 25.41 | 0.002608 | 10 | 2 | |
regulation of sensory perception | 51931 | 0.03% | 0.82% | 25.41 | 0.002608 | 10 | 2 | ||
Biological Regulation/Multicellular Organismal Process | bone resorption | 45453 | 0.13% | 1.23% | 9.77 | 0.003323 | 39 | 3 | |
Cellular Process | collagen fibril organization | 30199 | 0.05% | 1.23% | 23.82 | 0.000244 | 16 | 3 | |
extracellular matrix organization and biogenesis | 30198 | 0.25% | 2.05% | 8.36 | 0.000309 | 76 | 5 | ||
Developmental Process/Multicellular Organismal Process | cartilage development | 51216 | 0.18% | 2.46% | 13.37 | 0.000005 | 57 | 6 | |
bone mineralization | 30282 | 0.13% | 1.23% | 9.77 | 0.003323 | 39 | 3 | ||
ossification | 1503 | 0.59% | 4.92% | 8.33 | 0.000000 | 183 | 12 | ||
biomineral formation | 31214 | 0.59% | 4.92% | 8.33 | 0.000000 | 183 | 12 | ||
skeletal development | 1501 | 1.09% | 8.20% | 7.54 | 0.000000 | 337 | 20 | ||
tissue development | 9888 | 1.52% | 7.79% | 5.11 | 0.000000 | 472 | 19 | ||
Developmental Process/Multicellular Organismal Process/Cellular Process/Biological Adhesion | cartilage condensation | 1502 | 0.06% | 1.23% | 19.06 | 0.000481 | 20 | 3 | |
Localization | iron ion transport | 6826 | 0.12% | 1.64% | 14.12 | 0.000172 | 36 | 4 | |
transition metal ion transport | 41 | 0.23% | 1.64% | 7.26 | 0.002055 | 70 | 4 | ||
phosphate transport | 6817 | 0.35% | 2.05% | 5.88 | 0.001454 | 108 | 5 | ||
Metabolic Process | biopolymer biosynthetic process | 43284 | 0.25% | 1.64% | 6.43 | 0.003139 | 79 | 4 | |
carbohydrate catabolic process | 16052 | 0.41% | 2.46% | 5.96 | 0.000473 | 128 | 6 | ||
Metabolic Process/Cellular Process | translational elongation | 6414 | 0.13% | 1.64% | 12.40 | 0.000284 | 41 | 4 | |
glycolysis | 6096 | 0.22% | 2.46% | 11.05 | 0.000016 | 69 | 6 | ||
nicotinamide metabolic process | 6769 | 0.11% | 1.23% | 10.89 | 0.002456 | 35 | 3 | ||
pyridine nucleotide metabolic process | 19362 | 0.12% | 1.23% | 10.03 | 0.003092 | 38 | 3 | ||
glucose catabolic process | 6007 | 0.27% | 2.46% | 9.07 | 0.000050 | 84 | 6 | ||
hexose catabolic process | 19320 | 0.29% | 2.46% | 8.47 | 0.000073 | 90 | 6 | ||
monosaccharide catabolic process | 46365 | 0.29% | 2.46% | 8.47 | 0.000073 | 90 | 6 | ||
alcohol catabolic process | 46164 | 0.30% | 2.46% | 8.20 | 0.000087 | 93 | 6 | ||
water-soluble vitamin metabolic process | 6767 | 0.25% | 1.64% | 6.60 | 0.002872 | 77 | 4 | ||
oxygen and reactive oxygen species metabolic process | 6800 | 0.60% | 3.69% | 6.11 | 0.000016 | 187 | 9 | ||
cellular carbohydrate catabolic process | 44275 | 0.40% | 2.46% | 6.10 | 0.000418 | 125 | 6 | ||
glucose metabolic process | 6006 | 0.55% | 3.28% | 5.94 | 0.000058 | 171 | 8 | ||
group transfer coenzyme metabolic process | 6752 | 0.28% | 1.64% | 5.84 | 0.004369 | 87 | 4 | ||
ATP metabolic process | 46034 | 0.29% | 1.64% | 5.71 | 0.004719 | 89 | 4 | ||
translation | 6412 | 1.91% | 10.25% | 5.37 | 0.000000 | 591 | 25 | ||
Multicellular Organismal Process | tissue remodeling | 48771 | 0.75% | 6.56% | 8.76 | 0.000000 | 232 | 16 | |
bone remodeling | 46849 | 0.68% | 5.74% | 8.47 | 0.000000 | 210 | 14 | ||
Obsolete Biological Process | tricarboxylic acid cycle intermediate metabolic process | 6100 | 0.09% | 1.23% | 13.14 | 0.001437 | 29 | 3 | |
Response to Stimulus | response to carbohydrate stimulus | 9743 | 0.10% | 1.23% | 12.70 | 0.001584 | 30 | 3 | |
response to hydrogen peroxide | 42542 | 0.14% | 1.23% | 9.07 | 0.004078 | 42 | 3 | ||
response to mechanical stimulus | 9612 | 0.19% | 1.64% | 8.47 | 0.001181 | 60 | 4 | ||
response to estrogen stimulus | 43627 | 0.25% | 1.64% | 6.60 | 0.002872 | 77 | 4 | ||
response to oxidative stress | 6979 | 0.52% | 2.87% | 5.52 | 0.000256 | 161 | 7 | ||
response to steroid hormone stimulus | 48545 | 0.47% | 2.46% | 5.19 | 0.000951 | 147 | 6 | ||
Cellular Component | Cell | cytosolic ribosome (sensu Eukaryota) | 5830 | 0.23% | 5.74% | 25.05 | 0.000000 | 71 | 14 |
cytosolic part | 44445 | 0.49% | 8.20% | 16.83 | 0.000000 | 151 | 20 | ||
extrinsic to membrane | 19898 | 0.36% | 2.05% | 5.72 | 0.001634 | 111 | 5 | ||
cytosol | 5829 | 2.52% | 13.52% | 5.36 | 0.000000 | 782 | 33 | ||
Cell/Macromolecular Complex | phosphopyruvate hydratase complex | 15 | 0.01% | 0.82% | 63.52 | 0.000364 | 4 | 2 | |
eukaryotic 48S initiation complex | 16283 | 0.10% | 3.69% | 36.89 | 0.000000 | 31 | 9 | ||
proton-transporting ATP synthase complex, catalytic core F(1) | 45261 | 0.03% | 0.82% | 31.76 | 0.001648 | 8 | 2 | ||
proton-transporting two-sector ATPase complex, catalytic domain | 33178 | 0.03% | 0.82% | 25.41 | 0.002608 | 10 | 2 | ||
eukaryotic 43S preinitiation complex | 16282 | 0.15% | 3.69% | 24.33 | 0.000000 | 47 | 9 | ||
hemoglobin complex | 5833 | 0.04% | 0.82% | 21.17 | 0.003765 | 12 | 2 | ||
proteasome core complex (sensu Eukaryota) | 5839 | 0.07% | 1.23% | 18.15 | 0.000557 | 21 | 3 | ||
proteasome complex (sensu Eukaryota) | 502 | 0.17% | 1.64% | 9.77 | 0.000698 | 52 | 4 | ||
Cell/Macromolecular Complex/Organelle | small ribosomal subunit | 15935 | 0.17% | 3.69% | 21.17 | 0.000000 | 54 | 9 | |
cytosolic large ribosomal subunit (sensu Eukaryota) | 5842 | 0.12% | 2.05% | 17.17 | 0.000010 | 37 | 5 | ||
large ribosomal subunit | 15934 | 0.20% | 2.05% | 10.25 | 0.000121 | 62 | 5 | ||
Cell/Organelle | rough endoplasmic reticulum membrane | 30867 | 0.03% | 0.82% | 28.23 | 0.002103 | 9 | 2 | |
Cell/Organelle/Envelope | mitochondrial respiratory chain | 5746 | 0.12% | 1.23% | 10.59 | 0.002658 | 36 | 3 | |
mitochondrial membrane part | 44455 | 0.21% | 1.64% | 7.82 | 0.001577 | 65 | 4 | ||
Extracellular Matrix | extracellular matrix | 31012 | 0.92% | 8.20% | 8.92 | 0.000000 | 285 | 20 | |
extracellular matrix part | 44420 | 0.43% | 3.69% | 8.53 | 0.000001 | 134 | 9 | ||
Extracellular Matrix/Extracellular Region | collagen type I | 5584 | 0.01% | 0.82% | 63.52 | 0.000364 | 4 | 2 | |
fibrillar collagen | 5583 | 0.06% | 1.64% | 28.23 | 0.000010 | 18 | 4 | ||
collagen | 5581 | 0.18% | 2.05% | 11.34 | 0.000075 | 56 | 5 | ||
basement membrane | 5604 | 0.26% | 1.64% | 6.27 | 0.003422 | 81 | 4 | ||
Extracellular Region/Extracellular Matrix | proteinaceous extracellular matrix | 5578 | 0.90% | 8.20% | 9.07 | 0.000000 | 280 | 20 | |
Organelle | cytosolic small ribosomal subunit (sensu Eukaryota) | 5843 | 0.10% | 3.69% | 36.89 | 0.000000 | 31 | 9 | |
ribosome | 5840 | 0.87% | 7.79% | 8.97 | 0.000000 | 269 | 19 | ||
Organelle/Macromolecular Complex | ribonucleoprotein complex | 30529 | 1.59% | 9.02% | 5.66 | 0.000000 | 494 | 22 | |
Molecular Function | Antioxidant Activity | antioxidant activity | 16209 | 0.23% | 1.64% | 7.06 | 0.002270 | 72 | 4 |
Binding | organic acid binding | 43177 | 0.01% | 0.82% | 84.70 | 0.000184 | 3 | 2 | |
rRNA binding | 19843 | 0.06% | 2.05% | 31.76 | 0.000000 | 20 | 5 | ||
calcium-dependent protein binding | 48306 | 0.04% | 0.82% | 23.10 | 0.003162 | 11 | 2 | ||
phosphatidylinositol-4,5-bisphosphate binding | 5546 | 0.04% | 0.82% | 19.55 | 0.004415 | 13 | 2 | ||
collagen binding | 5518 | 0.07% | 1.23% | 18.15 | 0.000557 | 21 | 3 | ||
calcium-dependent phospholipid binding | 5544 | 0.11% | 1.64% | 14.52 | 0.000154 | 35 | 4 | ||
hyaluronic acid binding | 5540 | 0.10% | 1.23% | 12.30 | 0.001740 | 31 | 3 | ||
NAD binding | 51287 | 0.14% | 1.64% | 11.55 | 0.000372 | 44 | 4 | ||
copper ion binding | 5507 | 0.35% | 2.46% | 7.06 | 0.000195 | 108 | 6 | ||
Catalytic Activity | phosphopyruvate hydratase activity | 4634 | 0.01% | 0.82% | 63.52 | 0.000364 | 4 | 2 | |
aldehyde-lyase activity | 16832 | 0.02% | 0.82% | 50.82 | 0.000603 | 5 | 2 | ||
procollagen-proline dioxygenase activity | 19798 | 0.02% | 0.82% | 36.30 | 0.001246 | 7 | 2 | ||
peptidyl-proline dioxygenase activity | 31543 | 0.02% | 0.82% | 36.30 | 0.001246 | 7 | 2 | ||
oxidoreductase activity, acting on heme group of donors, oxygen as acceptor | 16676 | 0.08% | 1.64% | 21.17 | 0.000034 | 24 | 4 | ||
oxidoreductase activity, acting on heme group of donors | 16675 | 0.08% | 1.64% | 21.17 | 0.000034 | 24 | 4 | ||
heme-copper terminal oxidase activity | 15002 | 0.08% | 1.64% | 21.17 | 0.000034 | 24 | 4 | ||
protein-lysine 6-oxidase activity | 4720 | 0.04% | 0.82% | 21.17 | 0.003765 | 12 | 2 | ||
threonine endopeptidase activity | 4298 | 0.07% | 1.23% | 18.15 | 0.000557 | 21 | 3 | ||
oxidoreductase activity, acting on peroxide as acceptor | 16684 | 0.17% | 1.64% | 9.77 | 0.000698 | 52 | 4 | ||
Catalytic Activity/Antioxidant Activity | peroxiredoxin activity | 51920 | 0.03% | 0.82% | 31.76 | 0.001648 | 8 | 2 | |
thioredoxin peroxidase activity | 8379 | 0.03% | 0.82% | 31.76 | 0.001648 | 8 | 2 | ||
peroxidase activity | 4601 | 0.17% | 1.64% | 9.77 | 0.000698 | 52 | 4 | ||
cytochrome-c oxidase activity | 4129 | 0.08% | 1.64% | 21.17 | 0.000034 | 24 | 4 | ||
Enzyme Regulator Activity | phospholipase inhibitor activity | 4859 | 0.05% | 1.23% | 22.42 | 0.000294 | 17 | 3 | |
Structural Molecule Activity | structural constituent of bone | 8147 | 0.03% | 1.23% | 47.64 | 0.000026 | 8 | 3 | |
extracellular matrix structural constituent | 5201 | 0.33% | 4.51% | 13.84 | 0.000000 | 101 | 11 | ||
structural constituent of ribosome | 3735 | 0.80% | 7.79% | 9.77 | 0.000000 | 247 | 19 | ||
structural molecule activity | 5198 | 2.59% | 13.93% | 5.37 | 0.000000 | 804 | 34 | ||
Transporter Activity | oxygen transporter activity | 5344 | 0.04% | 0.82% | 19.55 | 0.004415 | 13 | 2 | |
hydrogen ion transporter activity | 15078 | 0.40% | 2.87% | 7.17 | 0.000053 | 124 | 7 | ||
monovalent inorganic cation transporter activity | 15077 | 0.45% | 2.87% | 6.35 | 0.000111 | 140 | 7 |
Perichondrium
For the PC genes, all clusters from the 3×2 SOM showed the trend of hypothesized importance.(Supplementary Fig 3) Therefore, pathway analysis of the entire group of 18 PC genes passing the differential expression level filter was done.(Table V) Pathway analysis for all 18 PC genes passing the expression level filter showed enrichment of 52 pathways with a minimum of 2 probe sets per pathway from our data set. Of those 52, there were 5 molecular, 20 cellular, and 27 biological. (Table VI) Only 15 pathways (19%) involved 5 or more probe sets from our data, and 4 pathways (8%) were involved in BCMSD. However, none of those 4 pathways involving BCMSD involved 5 or more probe sets from our data.(Table III)
Table V.
Fold changes of 18 genes isolated from irradiated PC chondrocytes normalized to non-irradiated PC chondrocytes over time within the 52 significantly enhanced pathways shown in Table VI. Red indicates significantly upregulated fold changes while green indicates significantly downregulated fold changes. Note that all of the genes showed the predicted pattern of early upregulation followed by progressive decrease
Differential Expression of 18 genes in the PC which follow our hypothesized pattern | ||||||||
---|---|---|---|---|---|---|---|---|
99.9% CI | ||||||||
Log2 ratio (R/L) | ||||||||
7d | 11d | 16d | ||||||
Mean Log2 | 0.01 | 0.00 | -0.01 | |||||
StDev | 0.54 | 0.41 | 0.45 | |||||
+99.9 CL | 1.83 | 1.37 | 1.51 | |||||
# Incr 99.9CL | 209 | 73 | 132 | |||||
-99.9 CL | -1.82 | -1.38 | -1.53 | |||||
# Decr 99.9CL | 279 | 201 | 270 | |||||
Log2 ratio (R/L) | Fold Change | |||||||
Probe ID | Gene Title | Gene Symbol | 7d | 11d | 16d | 7days | 11days | 16days |
1398882_at | ribosomal protein S5 | Rps5 | 4.85 | -0.18 | -1.28 | 28.80 | -1.13 | -2.43 |
1398324_at | similar to 60S ribosomal protein L18a | MGC72957 | 4.57 | -0.24 | -1.39 | 23.75 | -1.18 | -2.62 |
1371307_at | ribosomal protein, large, P1 | Rplp1 | 4.27 | -0.71 | -2.20 | 19.24 | -1.64 | -4.60 |
1367721_at | syndecan 4 | Sdc4 | 4.21 | -0.45 | -1.16 | 18.50 | -1.37 | -2.24 |
1367595_s_at | beta-2 microglobulin | B2m | 4.12 | -0.99 | -1.10 | 17.36 | -1.99 | -2.14 |
1367635_at | prolyl 4-hydroxylase, beta polypeptide | P4hb | 3.95 | 0.48 | -1.09 | 15.42 | 1.39 | -2.13 |
1393240_at | EGF-containing fibulin-like extracellular matrix protein 2 | Efemp2 | 3.94 | 0.36 | -2.38 | 15.30 | 1.28 | -5.21 |
1370341_at | enolase 2, gamma | Eno2 | 3.92 | 1.53 | 0.16 | 15.09 | 2.89 | 1.11 |
1392171_at | chitinase 3-like 1 | Chi3l1 | 3.90 | 0.07 | -1.28 | 14.93 | 1.05 | -2.43 |
1367571_a_at | insulin-like growth factor 2 | Igf2 | 3.72 | -0.03 | -0.98 | 13.15 | -1.02 | -1.97 |
1371305_at | ribosomal protein L8 | Rpl8 | 3.68 | 0.29 | -0.23 | 12.79 | 1.22 | -1.17 |
1375066_at | similar to RIKEN cDNA 6330512M04 gene (predicted) | RGD1563319_predicted | 3.61 | -0.50 | -1.02 | 12.21 | -1.42 | -2.03 |
1377472_at | Transcribed locus | 3.61 | -0.02 | -1.02 | 12.18 | -1.02 | -2.03 | |
1367569_at | ribosomal protein SA | Rpsa | 3.50 | 0.32 | -2.44 | 11.28 | 1.25 | -5.42 |
1367560_at | acidic ribosomal phosphoprotein P0 | Arbp | 3.48 | -0.13 | -2.31 | 11.16 | -1.09 | -4.96 |
1369113_at | gremlin 1 homolog, cysteine knot superfamily (Xenopus laevis) | Grem1 | 1.88 | 0.30 | -3.92 | 3.69 | 1.23 | -15.17 |
1370155_at | procollagen, type I, alpha 2 | Col1a2 | 1.75 | -0.78 | -3.42 | 3.37 | -1.71 | -10.67 |
1375001_at | Transcribed locus | 1.27 | 0.28 | -5.59 | 2.42 | 1.21 | -48.28 | |
1373829_at | Transcribed locus | 0.78 | -0.49 | -3.99 | 1.71 | -1.40 | -15.86 | |
Falls within +99.9% CI | Fold Change +2 | |||||||
Falls within +99.9% CI | Fold Change -2 |
Table VI.
PC 52 enriched pathways from the differential expression analysis showing hypergeometric p values less than 0.05. These pathways were derived from the entire PC gene list showing differential upregulation at 7 days (compared to non-irradiated chondrocytes) followed by a decrease at 11 and 16 days. Gray indicates a pathways association with BCMSD
PC Enriched Pathways after Differential Expression Analysis of 18 Genes in Gene List | |||||||||
---|---|---|---|---|---|---|---|---|---|
GO Parent Category | GO Term | GO (Child)Term | GO ID | % of Array | % of list | Fold Enrichment | P value | Total Probe Sets On Array | Probe Sets in Your List |
Biological Process | Biological Regulation | regulation of cell size | 8361 | 0.70% | 11.11% | 15.87 | 0.006676 | 217 | 2 |
regulation of biological quality | 65008 | 2.94% | 16.67% | 5.68 | 0.013177 | 910 | 3 | ||
cell growth | 16049 | 0.69% | 11.11% | 16.10 | 0.006502 | 214 | 2 | ||
Cellular Process | transmembrane receptor protein tyrosine kinase signaling pathway | 7169 | 0.96% | 16.67% | 17.34 | 0.000622 | 298 | 3 | |
enzyme linked receptor protein signaling pathway | 7167 | 1.37% | 16.67% | 12.19 | 0.001689 | 424 | 3 | ||
cell-cell signaling | 7267 | 3.27% | 16.67% | 5.10 | 0.017314 | 1014 | 3 | ||
Developmental Process | morphogenesis of an epithelium | 2009 | 0.48% | 11.11% | 22.96 | 0.003296 | 150 | 2 | |
Developmental Process/Multicellular Organismal Process | embryonic morphogenesis | 48598 | 0.61% | 11.11% | 18.32 | 0.005083 | 188 | 2 | |
skeletal development | 1501 | 1.09% | 16.67% | 15.33 | 0.000883 | 337 | 3 | ||
organ morphogenesis | 9887 | 1.87% | 16.67% | 8.89 | 0.004030 | 581 | 3 | ||
embryonic development | 9790 | 1.42% | 11.11% | 7.81 | 0.024589 | 441 | 2 | ||
organ development | 48513 | 5.52% | 27.78% | 5.04 | 0.002085 | 1710 | 5 | ||
Growth | growth | 40007 | 1.34% | 11.11% | 8.32 | 0.021975 | 414 | 2 | |
Metabolic Process | biopolymer biosynthetic process | 43284 | 0.25% | 11.11% | 43.60 | 0.000943 | 79 | 2 | |
carbohydrate catabolic process | 16052 | 0.41% | 11.11% | 26.91 | 0.002425 | 128 | 2 | ||
carbohydrate metabolic process | 5975 | 1.81% | 11.11% | 6.13 | 0.037495 | 562 | 2 | ||
nitrogen compound metabolic process | 6807 | 2.00% | 11.11% | 5.56 | 0.044269 | 620 | 2 | ||
macromolecule biosynthetic process | 9059 | 2.96% | 33.33% | 11.26 | 0.000009 | 918 | 6 | ||
macromolecule catabolic process | 9057 | 1.50% | 11.11% | 7.42 | 0.026897 | 464 | 2 | ||
biosynthetic process | 9058 | 5.41% | 33.33% | 6.16 | 0.000238 | 1678 | 6 | ||
Metabolic Process/Cellular Process | translational elongation | 6414 | 0.13% | 11.11% | 84.01 | 0.000256 | 41 | 2 | |
cellular carbohydrate catabolic process | 44275 | 0.40% | 11.11% | 27.56 | 0.002316 | 125 | 2 | ||
translation | 6412 | 1.91% | 33.33% | 17.48 | 0.000001 | 591 | 6 | ||
cellular macromolecule catabolic process | 44265 | 1.20% | 11.11% | 9.23 | 0.018220 | 373 | 2 | ||
cellular carbohydrate metabolic process | 44262 | 1.36% | 11.11% | 8.16 | 0.022738 | 422 | 2 | ||
amine metabolic process | 9308 | 1.87% | 11.11% | 5.95 | 0.039445 | 579 | 2 | ||
cellular catabolic process | 44248 | 2.09% | 11.11% | 5.31 | 0.047774 | 649 | 2 | ||
Cellular Component | Cell | cytosolic part | 44445 | 0.49% | 27.78% | 57.03 | 0.000000 | 151 | 5 |
cell surface | 9986 | 0.80% | 11.11% | 13.95 | 0.008520 | 247 | 2 | ||
cytosol | 5829 | 2.52% | 27.78% | 11.01 | 0.000062 | 782 | 5 | ||
Cell/Macromolecular Process | eukaryotic 48S initiation complex | 16283 | 0.10% | 11.11% | 111.11 | 0.000146 | 31 | 2 | |
eukaryotic 43S preinitiation complex | 16282 | 0.15% | 11.11% | 73.29 | 0.000336 | 47 | 2 | ||
ribonucleoprotein complex | 30529 | 1.59% | 33.33% | 20.92 | 0.000000 | 494 | 6 | ||
Extracellular Matrix | extracellular matrix | 31012 | 0.92% | 16.67% | 18.13 | 0.000547 | 285 | 3 | |
Extracellular Region | extracellular region part | 44421 | 6.97% | 44.44% | 6.37 | 0.000012 | 2162 | 8 | |
extracellular region | 5576 | 7.58% | 44.44% | 5.86 | 0.000022 | 2351 | 8 | ||
extracellular space | 5615 | 6.65% | 38.89% | 5.85 | 0.000085 | 2062 | 7 | ||
Extracellular | proteinaceous extracellular matrix | 5578 | 0.90% | 16.67% | 18.45 | 0.000520 | 280 | 3 | |
Macromolecular Complex | macromolecular complex | 32991 | 8.61% | 44.44% | 5.16 | 0.000053 | 2669 | 8 | |
Organelle | non-membrane-bound organelle | 43228 | 5.76% | 33.33% | 5.79 | 0.000330 | 1785 | 6 | |
Organelle/Cell | intracellular non-membrane-bound organelle | 43232 | 5.76% | 33.33% | 5.79 | 0.000330 | 1785 | 6 | |
Organelle/Cell/Macromolecular Complex | cytosolic small ribosomal subunit (sensu Eukaryota) | 5843 | 0.10% | 11.11% | 111.11 | 0.000146 | 31 | 2 | |
cytosolic ribosome (sensu Eukaryota) | 5830 | 0.23% | 22.22% | 97.03 | 0.000000 | 71 | 4 | ||
cytosolic large ribosomal subunit (sensu Eukaryota) | 5842 | 0.12% | 11.11% | 93.09 | 0.000208 | 37 | 2 | ||
small ribosomal subunit | 15935 | 0.17% | 11.11% | 63.79 | 0.000444 | 54 | 2 | ||
large ribosomal subunit | 15934 | 0.20% | 11.11% | 55.56 | 0.000584 | 62 | 2 | ||
ribosome | 5840 | 0.87% | 33.33% | 38.41 | 0.000000 | 269 | 6 | ||
Molecular Function | Binding | RNA binding | 3723 | 2.32% | 16.67% | 7.19 | 0.007141 | 719 | 3 |
Molecular Transducer | transmembrane receptor activity | 4888 | 3.22% | 16.67% | 5.18 | 0.016598 | 997 | 3 | |
Structural Molecule Activity | structural constituent of ribosome | 3735 | 0.80% | 33.33% | 41.84 | 0.000000 | 247 | 6 | |
extracellular matrix structural constituent | 5201 | 0.33% | 11.11% | 34.10 | 0.001528 | 101 | 2 | ||
structural molecule activity | 5198 | 2.59% | 44.44% | 17.14 | 0.000000 | 804 | 8 |
Hypertrophic Zone
For the HZ genes, all clusters from the 4×3 SOM showed the temporal trend of hypothesized importance.(Supplementary Fig 4) Therefore pathway analysis of the entire group of 245 HZ genes was done.(Table VII) For pathway analysis of all 245 HZ genes meeting the expression level filter, 201 pathways showed enrichment with a minimum 2 probe sets per pathway. Of these, there were 39 molecular, 21 cellular, and 141 biological pathways. Nineteen pathways (9%) involved BCMSD. (Table VII) Seventy-two pathways (36%) involved 5 or more probe sets from the current data set. There were 12 pathways (6%) that involved BCMSD as well as including a minimum of a 5 probe sets.(Table III)
Table VII.
HZ 201 enriched pathways from differential expression analysis showing hypergeometric p values less than 0.05. These pathways were derived from the 245 HZ genes showing differential upregulation at 7 days (compared to non-irradiated chondrocytes) followed by a decrease at 11 and 16 days. Gray indicates a pathways association with BCMSD
HZ Enriched Pathways after Differential Expression Analysis of 245 Genes in Gene List | |||||||||
---|---|---|---|---|---|---|---|---|---|
GO Parent Category | GO Term | GO (Child)Term | GO ID | % of Array | % of list | Fold Enrichment | P value | Total Probe Sets On Array | Probe Sets in Your List |
Biological Process | Biological Process/Developmental Process/Multicellular Organismal Process/Cellular Process | regulation of dendrite development | 50773 | 0.07% | 0.82% | 11.00 | 0.013340 | 23 | 2 |
negative regulation of neurogenesis | 50768 | 0.10% | 0.82% | 8.16 | 0.023022 | 31 | 2 | ||
positive regulation of neurogenesis | 50769 | 0.15% | 1.22% | 7.91 | 0.005926 | 48 | 3 | ||
regulation of neurogenesis | 50767 | 0.33% | 2.04% | 6.26 | 0.001110 | 101 | 5 | ||
Biological Regulation | regulation of cell size | 8361 | 0.70% | 3.67% | 5.25 | 0.000052 | 217 | 9 | |
negative regulation of protein kinase activity | 6469 | 0.24% | 1.22% | 5.06 | 0.018716 | 75 | 3 | ||
Biological Regulation/Celluilar Process | negative regulation of cyclin-dependent protein kinase activity | 45736 | 0.04% | 0.82% | 23.01 | 0.003187 | 11 | 2 | |
negative regulation of progression through cell cycle | 45786 | 0.53% | 2.86% | 5.37 | 0.000303 | 165 | 7 | ||
negative regulation of Ras protein signal transduction | 46580 | 0.04% | 0.82% | 23.01 | 0.003187 | 11 | 2 | ||
negative regulation of small GTPase mediated signal transduction | 51058 | 0.04% | 0.82% | 19.47 | 0.004450 | 13 | 2 | ||
regulation of cyclin-dependent protein kinase activity | 79 | 0.15% | 1.22% | 8.44 | 0.004978 | 45 | 3 | ||
iron ion homeostasis | 6879 | 0.11% | 0.82% | 7.67 | 0.025732 | 33 | 2 | ||
positive regulation of mononuclear cell proliferation | 32946 | 0.11% | 0.82% | 7.67 | 0.025732 | 33 | 2 | ||
regulation of progression through mitotic cell cycle | 7346 | 0.13% | 0.82% | 6.33 | 0.035973 | 40 | 2 | ||
Biological Regulation/Cellular Process/Growth | cell growth | 16049 | 0.69% | 3.67% | 5.32 | 0.000047 | 214 | 9 | |
Biological Regulation/Cellular Process/Immune System Process | positive regulation of lymphocyte proliferation | 50671 | 0.11% | 0.82% | 7.67 | 0.025732 | 33 | 2 | |
Biological Regulation/cellular Process/Localization | positive regulation of cell migration | 30335 | 0.12% | 1.22% | 9.99 | 0.003126 | 38 | 3 | |
positive regulation of cell motility | 51272 | 0.15% | 1.22% | 8.44 | 0.004978 | 45 | 3 | ||
Biological Regulation/Developmental Process | negative regulation of developmental process | 51093 | 0.38% | 2.04% | 5.36 | 0.002148 | 118 | 5 | |
Biological Regulation/Developmental Process/Multicellular Organismal Process | regulation of bone mineralization | 30500 | 0.07% | 0.82% | 11.50 | 0.012277 | 22 | 2 | |
Biological Regulation/Localization/Immune System Process/Cellular Process | positive regulation of leukocyte migration | 2687 | 0.01% | 0.82% | 126.53 | 0.000062 | 2 | 2 | |
regulation of leukocyte migration | 2685 | 0.01% | 0.82% | 63.27 | 0.000367 | 4 | 2 | ||
Biological Regulation/Locomotion | positive regulation of locomotion | 40017 | 0.15% | 1.22% | 8.44 | 0.004978 | 45 | 3 | |
Biological Regulation/Metabolic Process/Cellular Process | activation of NF-kappaB transcription factor | 51092 | 0.06% | 0.82% | 13.32 | 0.009305 | 19 | 2 | |
positive regulation of transcription factor activity | 51091 | 0.09% | 0.82% | 9.37 | 0.017934 | 27 | 2 | ||
regulation of transcription factor activity | 51090 | 0.15% | 0.82% | 5.62 | 0.043895 | 45 | 2 | ||
Biological Regulation/Multicellular Organismal Process | bone resorption | 45453 | 0.13% | 2.45% | 19.47 | 0.000001 | 39 | 6 | |
multicellular organismal homeostasis | 48871 | 0.15% | 2.45% | 15.82 | 0.000002 | 48 | 6 | ||
positive regulation of bone remodeling | 46852 | 0.07% | 0.82% | 11.50 | 0.012277 | 22 | 2 | ||
regulation of bone remodeling | 46850 | 0.21% | 1.22% | 5.93 | 0.012590 | 64 | 3 | ||
hemostasis | 7599 | 0.35% | 2.04% | 5.75 | 0.001600 | 110 | 5 | ||
Biological Regulation/Multicellular Organismal Process/Developmental Process | regulation of ossification | 30278 | 0.17% | 1.22% | 7.03 | 0.008108 | 54 | 3 | |
Biological Regulation/MulticellularOrganismal Process | tissue homeostasis | 1894 | 0.15% | 2.45% | 15.82 | 0.000002 | 48 | 6 | |
Bioogical Regulatio/Cellular Process/Developmental Process | negative regulation of cell differentiation | 45596 | 0.28% | 1.63% | 5.89 | 0.004259 | 86 | 4 | |
Cellular Process | collagen fibril organization | 30199 | 0.05% | 2.04% | 39.54 | 0.000000 | 16 | 5 | |
elastic fiber assembly | 48251 | 0.02% | 0.82% | 36.15 | 0.001256 | 7 | 2 | ||
extracellular matrix organization and biogenesis | 30198 | 0.25% | 5.31% | 21.64 | 0.000000 | 76 | 13 | ||
extracellular structure organization and biogenesis | 43062 | 0.53% | 5.31% | 9.97 | 0.000000 | 165 | 13 | ||
ER-nuclear signaling pathway | 6984 | 0.09% | 0.82% | 9.04 | 0.019162 | 28 | 2 | ||
epithelial cell proliferation | 50673 | 0.18% | 1.22% | 6.78 | 0.008920 | 56 | 3 | ||
transforming growth factor beta receptor signaling pathway | 7179 | 0.26% | 1.63% | 6.33 | 0.003325 | 80 | 4 | ||
Cellular Process/Biological Adhesion | cell-matrix adhesion | 7160 | 0.32% | 2.04% | 6.39 | 0.001018 | 99 | 5 | |
cell-substrate adhesion | 31589 | 0.34% | 2.04% | 6.08 | 0.001259 | 104 | 5 | ||
Cellular Process/Biological Adhesion/Developmental Process/Multicellular Organismal Process | cartilage condensation | 1502 | 0.06% | 1.63% | 25.31 | 0.000016 | 20 | 4 | |
Cellular Process/Biological Regulation | positive regulation of epithelial cell proliferation | 50679 | 0.09% | 0.82% | 9.37 | 0.017934 | 27 | 2 | |
regulation of epithelial cell proliferation | 50678 | 0.14% | 0.82% | 5.75 | 0.042275 | 44 | 2 | ||
Cellular Process/Localization | protein targeting to membrane | 6612 | 0.10% | 0.82% | 7.91 | 0.024364 | 32 | 2 | |
Cellular Process/Metabolic Process | peptide cross-linking | 18149 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | |
proteoglycan biosynthetic process | 30166 | 0.07% | 0.82% | 11.00 | 0.013340 | 23 | 2 | ||
sphingolipid biosynthetic process | 30148 | 0.08% | 0.82% | 10.54 | 0.014439 | 24 | 2 | ||
purine nucleoside triphosphate biosynthetic process | 9145 | 0.23% | 2.04% | 9.04 | 0.000216 | 70 | 5 | ||
ribonucleoside triphosphate biosynthetic process | 9201 | 0.23% | 2.04% | 9.04 | 0.000216 | 70 | 5 | ||
purine ribonucleoside triphosphate biosynthetic process | 9206 | 0.23% | 2.04% | 9.04 | 0.000216 | 70 | 5 | ||
nucleoside triphosphate biosynthetic process | 9142 | 0.24% | 2.04% | 8.55 | 0.000279 | 74 | 5 | ||
ATP metabolic process | 46034 | 0.29% | 2.45% | 8.53 | 0.000070 | 89 | 6 | ||
actin filament polymerization | 30041 | 0.15% | 1.22% | 7.91 | 0.005926 | 48 | 3 | ||
ribonucleoside triphosphate metabolic process | 9199 | 0.32% | 2.45% | 7.75 | 0.000118 | 98 | 6 | ||
purine ribonucleoside triphosphate metabolic process | 9205 | 0.32% | 2.45% | 7.75 | 0.000118 | 98 | 6 | ||
purine nucleoside triphosphate metabolic process | 9144 | 0.32% | 2.45% | 7.67 | 0.000125 | 99 | 6 | ||
nucleoside triphosphate metabolic process | 9141 | 0.34% | 2.45% | 7.16 | 0.000180 | 106 | 6 | ||
purine ribonucleotide biosynthetic process | 9152 | 0.31% | 2.04% | 6.52 | 0.000932 | 97 | 5 | ||
actin filament depolymerization | 30042 | 0.13% | 0.82% | 6.49 | 0.034445 | 39 | 2 | ||
purine ribonucleotide metabolic process | 9150 | 0.41% | 2.45% | 5.98 | 0.000464 | 127 | 6 | ||
ribonucleotide biosynthetic process | 9260 | 0.34% | 2.04% | 5.97 | 0.001366 | 106 | 5 | ||
hexose catabolic process | 19320 | 0.29% | 1.63% | 5.62 | 0.004967 | 90 | 4 | ||
monosaccharide catabolic process | 46365 | 0.29% | 1.63% | 5.62 | 0.004967 | 90 | 4 | ||
actin polymerization and/or depolymerization | 8154 | 0.30% | 1.63% | 5.44 | 0.005544 | 93 | 4 | ||
alcohol catabolic process | 46164 | 0.30% | 1.63% | 5.44 | 0.005544 | 93 | 4 | ||
ribonucleotide metabolic process | 9259 | 0.45% | 2.45% | 5.38 | 0.000788 | 141 | 6 | ||
coenzyme biosynthetic process | 9108 | 0.40% | 2.04% | 5.10 | 0.002638 | 124 | 5 | ||
Cellular Process/Response to Stimulus | unfolded protein response | 30968 | 0.06% | 0.82% | 12.65 | 0.010258 | 20 | 2 | |
Developmental Process | aging | 7568 | 0.20% | 1.22% | 6.22 | 0.011135 | 61 | 3 | |
Developmental Process/Multicellular Organismal Process | bone mineralization | 30282 | 0.13% | 2.04% | 16.22 | 0.000013 | 39 | 5 | |
cartilage development | 51216 | 0.18% | 2.45% | 13.32 | 0.000006 | 57 | 6 | ||
ossification | 1503 | 0.59% | 4.49% | 7.61 | 0.000000 | 183 | 11 | ||
biomineral formation | 31214 | 0.59% | 4.49% | 7.61 | 0.000000 | 183 | 11 | ||
skeletal development | 1501 | 1.09% | 7.35% | 6.76 | 0.000000 | 337 | 18 | ||
ureteric bud development | 1657 | 0.15% | 0.82% | 5.50 | 0.045529 | 46 | 2 | ||
Developmental Process/Multicellular Organismal Process/Biological Regulation/Cellular Process | regulation of dendrite morphogenesis | 48814 | 0.05% | 0.82% | 14.89 | 0.007518 | 17 | 2 | |
Developmental Process/Multicellular Organismal Process/Cellular Process | dendrite morphogenesis | 48813 | 0.07% | 0.82% | 11.50 | 0.012277 | 22 | 2 | |
Developmental Process/Multicellular Organismal Process/Cellular Process/Immune System Process | macrophage differentiation | 30225 | 0.05% | 0.82% | 14.89 | 0.007518 | 17 | 2 | |
Developmental Process/Multicellular Organismal Process/Multicellular Organismal Process | osteoblast differentiation | 1649 | 0.17% | 1.63% | 9.73 | 0.000708 | 52 | 4 | |
Localization | long-chain fatty acid transport | 15909 | 0.04% | 0.82% | 19.47 | 0.004450 | 13 | 2 | |
fatty acid transport | 15908 | 0.06% | 0.82% | 12.65 | 0.010258 | 20 | 2 | ||
energy coupled proton transport, down electrochemical gradient | 15985 | 0.18% | 2.04% | 11.30 | 0.000076 | 56 | 5 | ||
iron ion transport | 6826 | 0.12% | 1.22% | 10.54 | 0.002688 | 36 | 3 | ||
phosphate transport | 6817 | 0.35% | 3.27% | 9.37 | 0.000002 | 108 | 8 | ||
proton transport | 15992 | 0.35% | 2.45% | 6.90 | 0.000219 | 110 | 6 | ||
hydrogen transport | 6818 | 0.37% | 2.45% | 6.66 | 0.000265 | 114 | 6 | ||
transition metal ion transport | 41 | 0.23% | 1.22% | 5.42 | 0.015780 | 70 | 3 | ||
Localization/Cellular Process/Immune System Process | leukocyte migration | 50900 | 0.18% | 1.63% | 9.04 | 0.000932 | 56 | 4 | |
Localization/Cellular Process/Metabolic Process | ATP synthesis coupled proton transport | 15986 | 0.18% | 2.04% | 11.30 | 0.000076 | 56 | 5 | |
Metabolic Process | sequestering of lipid | 19915 | 0.03% | 0.82% | 25.31 | 0.002629 | 10 | 2 | |
collagen metabolic process | 32963 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | ||
multicellular organismal macromolecule metabolic process | 44259 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | ||
multicellular organismal macromolecule catabolic process | 44266 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | ||
multicellular organismal protein metabolic process | 44268 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | ||
peptidoglycan metabolic process | 270 | 0.06% | 0.82% | 13.32 | 0.009305 | 19 | 2 | ||
protein tetramerization | 51262 | 0.09% | 0.82% | 9.37 | 0.017934 | 27 | 2 | ||
Metabolic Process/Cellular Process | nucleoside phosphate metabolic process | 6753 | 0.20% | 2.04% | 10.37 | 0.000114 | 61 | 5 | |
ATP biosynthetic process | 6754 | 0.20% | 2.04% | 10.37 | 0.000114 | 61 | 5 | ||
N-acetylglucosamine metabolic process | 6044 | 0.08% | 0.82% | 9.73 | 0.016737 | 26 | 2 | ||
glutathione metabolic process | 6749 | 0.08% | 0.82% | 9.73 | 0.016737 | 26 | 2 | ||
glucosamine metabolic process | 6041 | 0.09% | 0.82% | 9.04 | 0.019162 | 28 | 2 | ||
proteasomal ubiquitin-dependent protein catabolic process | 43161 | 0.09% | 0.82% | 9.04 | 0.019162 | 28 | 2 | ||
oxidative phosphorylation | 6119 | 0.29% | 2.45% | 8.34 | 0.000079 | 91 | 6 | ||
amino sugar metabolic process | 6040 | 0.10% | 0.82% | 8.16 | 0.023022 | 31 | 2 | ||
proteoglycan metabolic process | 6029 | 0.10% | 0.82% | 7.91 | 0.024364 | 32 | 2 | ||
glycolysis | 6096 | 0.22% | 1.63% | 7.34 | 0.001981 | 69 | 4 | ||
group transfer coenzyme metabolic process | 6752 | 0.28% | 2.04% | 7.27 | 0.000578 | 87 | 5 | ||
glucose catabolic process | 6007 | 0.27% | 1.63% | 6.03 | 0.003931 | 84 | 4 | ||
purine nucleotide biosynthetic process | 6164 | 0.35% | 2.04% | 5.86 | 0.001480 | 108 | 5 | ||
sphingolipid metabolic process | 6665 | 0.22% | 1.22% | 5.58 | 0.014676 | 68 | 3 | ||
purine nucleotide metabolic process | 6163 | 0.45% | 2.45% | 5.46 | 0.000734 | 139 | 6 | ||
oxygen and reactive oxygen species metabolic process | 6800 | 0.60% | 3.27% | 5.41 | 0.000109 | 187 | 8 | ||
cellular respiration | 45333 | 0.15% | 0.82% | 5.27 | 0.048844 | 48 | 2 | ||
Metabolic Process/Multicellular Organismal Process | collagen catabolic process | 30574 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | |
multicellular organismal protein catabolic process | 44254 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | ||
multicellular organismal catabolic process | 44243 | 0.05% | 0.82% | 16.87 | 0.005896 | 15 | 2 | ||
multicellular organismal metabolic process | 44236 | 0.07% | 0.82% | 12.05 | 0.011249 | 21 | 2 | ||
Multicellular Organismal Process | protein digestion | 44256 | 0.05% | 0.82% | 18.08 | 0.005151 | 14 | 2 | |
bone remodeling | 46849 | 0.68% | 5.71% | 8.44 | 0.000000 | 210 | 14 | ||
tissue remodeling | 48771 | 0.75% | 6.12% | 8.18 | 0.000000 | 232 | 15 | ||
coagulation | 50817 | 0.34% | 2.04% | 6.08 | 0.001259 | 104 | 5 | ||
Obsolete Biological Process | tricarboxylic acid cycle intermediate metabolic process | 6100 | 0.09% | 0.82% | 8.73 | 0.020420 | 29 | 2 | |
Reproduction/Multicellular Organismal Process/Developmental Process/Multi-organism Process | embryo implantation | 7566 | 0.08% | 0.82% | 10.12 | 0.015571 | 25 | 2 | |
Response to Stimulus | response to hexose stimulus | 9746 | 0.08% | 1.63% | 20.24 | 0.000041 | 25 | 4 | |
Response to Stimulus | response to glucose stimulus | 9749 | 0.08% | 1.63% | 20.24 | 0.000041 | 25 | 4 | |
response to carbohydrate stimulus | 9743 | 0.10% | 1.63% | 16.87 | 0.000085 | 30 | 4 | ||
response to organic cyclic substance | 14070 | 0.07% | 0.82% | 12.05 | 0.011249 | 21 | 2 | ||
response to glucocorticoid stimulus | 51384 | 0.14% | 1.63% | 12.05 | 0.000317 | 42 | 4 | ||
response to steroid hormone stimulus | 48545 | 0.47% | 4.08% | 8.61 | 0.000000 | 147 | 10 | ||
wound healing | 42060 | 0.70% | 4.49% | 6.38 | 0.000001 | 218 | 11 | ||
acute-phase response | 6953 | 0.13% | 0.82% | 6.17 | 0.037521 | 41 | 2 | ||
response to hormone stimulus | 9725 | 0.73% | 4.49% | 6.16 | 0.000002 | 226 | 11 | ||
response to hydrogen peroxide | 42542 | 0.14% | 0.82% | 6.03 | 0.039088 | 42 | 2 | ||
response to drug | 42493 | 0.69% | 4.08% | 5.94 | 0.000007 | 213 | 10 | ||
response to oxidative stress | 6979 | 0.52% | 2.86% | 5.50 | 0.000262 | 161 | 7 | ||
response to organic substance | 10033 | 0.55% | 2.86% | 5.18 | 0.000373 | 171 | 7 | ||
Response to Stimulus/Biologocal Regulation/Multicellular Organismal Process | blood coagulation | 7596 | 0.33% | 2.04% | 6.14 | 0.001208 | 103 | 5 | |
Response to Stimulus/Localization/Immune System Process/Cellular Process | leukocyte chemotaxis | 30595 | 0.13% | 0.82% | 6.17 | 0.037521 | 41 | 2 | |
Cellular Component | Cell | lipid particle | 5811 | 0.02% | 0.82% | 36.15 | 0.001256 | 7 | 2 |
ER-Golgi intermediate compartment | 5793 | 0.09% | 1.22% | 13.56 | 0.001313 | 28 | 3 | ||
sarcoplasmic reticulum | 16529 | 0.11% | 0.82% | 7.67 | 0.025732 | 33 | 2 | ||
sarcoplasm | 16528 | 0.11% | 0.82% | 7.23 | 0.028544 | 35 | 2 | ||
ruffle | 1726 | 0.14% | 0.82% | 5.89 | 0.040673 | 43 | 2 | ||
sarcolemma | 42383 | 0.15% | 0.82% | 5.27 | 0.048844 | 48 | 2 | ||
Cell/Macromolecular Complex | eukaryotic 48S initiation complex | 16283 | 0.10% | 1.22% | 12.24 | 0.001760 | 31 | 3 | |
proton-transporting two-sector ATPase complex | 16469 | 0.22% | 2.04% | 9.44 | 0.000176 | 67 | 5 | ||
eukaryotic 43S preinitiation complex | 16282 | 0.15% | 1.22% | 8.08 | 0.005600 | 47 | 3 | ||
Cell/Organelle | integral to endoplasmic reticulum membrane | 30176 | 0.18% | 1.22% | 6.90 | 0.008508 | 55 | 3 | |
intrinsic to endoplasmic reticulum membrane | 31227 | 0.20% | 1.22% | 6.22 | 0.011135 | 61 | 3 | ||
Extracellular Matrix | extracellular matrix part | 44420 | 0.43% | 6.94% | 16.05 | 0.000000 | 134 | 17 | |
extracellular matrix | 31012 | 0.92% | 11.43% | 12.43 | 0.000000 | 285 | 28 | ||
Extracellular Region/Extracellular Matrix | collagen | 5581 | 0.18% | 3.27% | 18.08 | 0.000000 | 56 | 8 | |
basement membrane | 5604 | 0.26% | 4.49% | 17.18 | 0.000000 | 81 | 11 | ||
anchoring collagen | 30934 | 0.05% | 0.82% | 15.82 | 0.006686 | 16 | 2 | ||
proteinaceous extracellular matrix | 5578 | 0.90% | 11.43% | 12.65 | 0.000000 | 280 | 28 | ||
basal lamina | 5605 | 0.11% | 0.82% | 7.23 | 0.028544 | 35 | 2 | ||
Organelle/Macromolecular Complex/Cell | cytosolic small ribosomal subunit (sensu Eukaryota) | 5843 | 0.10% | 1.22% | 12.24 | 0.001760 | 31 | 3 | |
cytosolic ribosome (sensu Eukaryota) | 5830 | 0.23% | 1.63% | 7.13 | 0.002192 | 71 | 4 | ||
small ribosomal subunit | 15935 | 0.17% | 1.22% | 7.03 | 0.008108 | 54 | 3 | ||
Molecular Function | Antioxidant Activity | antioxidant activity | 16209 | 0.23% | 1.22% | 5.27 | 0.016925 | 72 | 3 |
Binding | S100 beta binding | 48154 | 0.01% | 0.82% | 84.35 | 0.000185 | 3 | 2 | |
calcium-dependent protein binding | 48306 | 0.04% | 1.63% | 46.01 | 0.000001 | 11 | 4 | ||
IgE binding | 19863 | 0.02% | 0.82% | 36.15 | 0.001256 | 7 | 2 | ||
collagen binding | 5518 | 0.07% | 2.45% | 36.15 | 0.000000 | 21 | 6 | ||
S100 alpha binding | 48155 | 0.03% | 0.82% | 31.63 | 0.001661 | 8 | 2 | ||
GABA receptor binding | 50811 | 0.03% | 0.82% | 28.12 | 0.002119 | 9 | 2 | ||
phosphatidylinositol-4,5-bisphosphate binding | 5546 | 0.04% | 0.82% | 19.47 | 0.004450 | 13 | 2 | ||
immunoglobulin binding | 19865 | 0.05% | 0.82% | 15.82 | 0.006686 | 16 | 2 | ||
ferric iron binding | 8199 | 0.06% | 0.82% | 14.06 | 0.008391 | 18 | 2 | ||
calcium-dependent phospholipid binding | 5544 | 0.11% | 1.22% | 10.85 | 0.002483 | 35 | 3 | ||
integrin binding | 5178 | 0.16% | 1.63% | 9.92 | 0.000659 | 51 | 4 | ||
selenium binding | 8430 | 0.09% | 0.82% | 8.73 | 0.020420 | 29 | 2 | ||
hyaluronic acid binding | 5540 | 0.10% | 0.82% | 8.16 | 0.023022 | 31 | 2 | ||
copper ion binding | 5507 | 0.35% | 2.45% | 7.03 | 0.000199 | 108 | 6 | ||
protein complex binding | 32403 | 0.41% | 2.45% | 6.03 | 0.000445 | 126 | 6 | ||
glycosaminoglycan binding | 5539 | 0.40% | 2.04% | 5.06 | 0.002727 | 125 | 5 | ||
Catalytic Activity | gelatinase B activity | 4229 | 0.01% | 0.82% | 126.53 | 0.000062 | 2 | 2 | |
collagenase activity | 8133 | 0.02% | 0.82% | 50.61 | 0.000608 | 5 | 2 | ||
protein-lysine 6-oxidase activity | 4720 | 0.04% | 1.22% | 31.63 | 0.000100 | 12 | 3 | ||
oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor | 16641 | 0.07% | 1.22% | 17.25 | 0.000647 | 22 | 3 | ||
oxidoreductase activity, acting on the CH-NH2 group of donors | 16638 | 0.09% | 1.22% | 14.06 | 0.001182 | 27 | 3 | ||
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors | 16706 | 0.09% | 0.82% | 9.37 | 0.017934 | 27 | 2 | ||
Catalytic Activity/Transporter Activity | hydrogen-exporting ATPase activity, phosphorylative mechanism | 8553 | 0.10% | 1.63% | 16.33 | 0.000097 | 31 | 4 | |
cation-transporting ATPase activity | 19829 | 0.29% | 2.04% | 7.03 | 0.000671 | 90 | 5 | ||
ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism | 15662 | 0.33% | 1.63% | 5.01 | 0.007282 | 101 | 4 | ||
Enzyme Regulator Activity | metalloendopeptidase inhibitor activity | 8191 | 0.03% | 0.82% | 25.31 | 0.002629 | 10 | 2 | |
phospholipase inhibitor activity | 4859 | 0.05% | 0.82% | 14.89 | 0.007518 | 17 | 2 | ||
endopeptidase inhibitor activity | 4866 | 0.55% | 2.86% | 5.21 | 0.000360 | 170 | 7 | ||
protease inhibitor activity | 30414 | 0.55% | 2.86% | 5.18 | 0.000373 | 171 | 7 | ||
enzyme inhibitor activity | 4857 | 1.06% | 5.31% | 5.00 | 0.000002 | 329 | 13 | ||
Molecular Transducer Activity | secretin-like receptor activity | 1633 | 0.12% | 0.82% | 6.66 | 0.032937 | 38 | 2 | |
Structural Molecule Activity | structural constituent of bone | 8147 | 0.03% | 0.82% | 31.63 | 0.001661 | 8 | 2 | |
extracellular matrix structural constituent | 5201 | 0.33% | 4.49% | 13.78 | 0.000000 | 101 | 11 | ||
Transcription Regulator Activity | specific RNA polymerase II transcription factor activity | 3704 | 0.14% | 0.82% | 5.75 | 0.042275 | 44 | 2 | |
Transporter Activity | hydrogen ion transporting ATPase activity, rotational mechanism | 46961 | 0.18% | 2.04% | 11.10 | 0.000083 | 57 | 5 | |
hydrogen ion transporting ATP synthase activity, rotational mechanism | 46933 | 0.17% | 1.63% | 9.37 | 0.000815 | 54 | 4 | ||
hydrogen ion transporter activity | 15078 | 0.40% | 2.45% | 6.12 | 0.000410 | 124 | 6 | ||
monovalent inorganic cation transporter activity | 15077 | 0.45% | 2.45% | 5.42 | 0.000760 | 140 | 6 |
Other overlapping and unique pathways not related to BCMSD are shown in Supplementary Table I for all zones. Gene Ontology trees for significantly enriched GO terms have been created using QuikGO (http://www.ebi.ac.uk/ego/) and can be found in supplementary Figures 5-8 for RZ, PZ, PC and HZ, respectively.
Real Time Results
To confirm the microarray results, real-time quantitative RT-PCR was performed with a set of rat specific primers and template cDNA generated by reverse-transcription PCR. The primers were designed to selected genes among the 18 genes listed in Table V and 37 genes in Table VIII that were determined to show significant early upregulation by microarray filters. These six genes included insulin-like growth factor 2 (Igf2), procollagen type I alpha 2 (Col1a2), matrix metallopeptidase 9 (Mmp9), parathyroid hormone receptor 1 (Pthr1), fibromodulin (Fmod), and aggrecan 1 (Agc1). Real time PCR LOG 2 ratios (R/L) of two genes, Igf2 and Col1a2, from irradiated (R) and non-irradiated (L) perichondrium over 7, 11 and 16 days showed significant early upregulation followed by later downregulation., this real time PCR data highly correlated with the microarray results (R>0.99, Table IX-A). Additionally, four genes, Mmp9, Pthr1, Fmod and Agc1, indicated significant early upregulated changes at 7 days in HZ and PZ. The LOG 2 ratios (R/L) of these genes were also validated with real time PCR, in which high correlation coefficients between the microarray and real time PCR data were present. (Table IX-B)
Table VIII.
Fold changes of 34 genes isolated from the 12 enriched pathways of Table III for PZ and HZ. Red indicates significantly upregulated fold changes while green indicates significantly downregulated fold changes. Note that all of the genes showed the predicted pattern of early upregulation followed by progressive decrease. * and † represent genes present in earlier single-fraction studies, references 16 and 17, respectively. NC represents genes with no significant change
Differentially expressed genes from within the 12 enriched pathways of Table III For PZ and HZ | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hypertophic Zone | Proliferative Zone | |||||||||||||
99.9% CI | 99.9% CI | |||||||||||||
Log2 ratio (R/L) | Log2 ratio (R/L) | |||||||||||||
7d | 11d | 16d | 7d | 11d | 16d | |||||||||
Mean Log2 | 0.05 | -0.02 | -0.01 | 0.04 | -0.01 | -0.01 | ||||||||
StDev | 0.89 | 0.60 | 0.52 | 0.80 | 0.46 | 0.38 | ||||||||
+99.9 CL | 3.07 | 2.02 | 1.74 | 2.73 | 1.53 | 1.26 | ||||||||
# Incr 99.9CL | 346 | 440 | 152 | 500 | 142 | 53 | ||||||||
-99.9 CL | -2.97 | -2.05 | -1.75 | -2.65 | -1.55 | -1.29 | ||||||||
# Decr 99.9CL | 441 | 41 | 238 | 29 | 135 | 310 | ||||||||
HZ | PZ | |||||||||||||
Log2 ratio (R/L) | Fold Change | Log2 ratio (R/L) | Fold Change | |||||||||||
Probe ID | Gene Name | Symbol | 7days | 11days | 16days | 7days | 11days | 16days | 7day | 11day | 16day | 7day | 11day | 16day |
1367568_a_at | matrix Gla protein | Mgp * | 8.07 | 5.07 | 2.37 | 268.16 | 33.58 | 5.18 | 3.90 | 2.54 | 1.85 | 14.90 | 5.81 | 3.60 |
1370234_at | fibronectin 1 | Fn1 * | 6.27 | 2.98 | 1.53 | 77.15 | 7.90 | 2.89 | NC | NC | NC | NC | NC | NC |
1369166_at | matrix metallopeptidase 9 | Mmp9 | 6.13 | 0.83 | -1.29 | 69.90 | 1.77 | -2.45 | NC | NC | NC | NC | NC | NC |
1371369_at | procollagen, type VI, alpha 2 | Col6a2 | 5.57 | 0.46 | -0.04 | 47.59 | 1.38 | -1.03 | 3.47 | 0.41 | 0.13 | 11.08 | 1.33 | 1.09 |
1370259_a_at | parathyroid hormone receptor 1 | Pthr1 † | 5.52 | -0.07 | 0.18 | 45.76 | -1.05 | 1.13 | 5.34 | -0.03 | 0.61 | 40.42 | -1.02 | 1.53 |
1367584_at | annexin A2 | Anxa2 | 5.27 | 0.59 | -0.46 | 38.65 | 1.50 | -1.37 | 4.39 | -0.01 | 0.58 | 20.98 | -1.01 | 1.49 |
1398270_at | bone morphogenetic protein 2 | Bmp2 † | 5.22 | 0.28 | 0.97 | 37.27 | 1.22 | 1.97 | NC | NC | NC | NC | NC | NC |
1367942_at | acid phosphatase 5, tartrate resistant | Acp5 | 5.04 | 1.10 | -2.16 | 32.86 | 2.15 | -4.48 | NC | NC | NC | NC | NC | NC |
1388618_at | nidogen 2 | Nid2 | 5.02 | 0.36 | -0.22 | 32.41 | 1.29 | -1.17 | NC | NC | NC | NC | NC | NC |
1367700_at | fibromodulin | Fmod * | 4.69 | 0.53 | -0.01 | 25.90 | 1.45 | -1.01 | 4.36 | 1.09 | -0.13 | 20.53 | 2.13 | -1.10 |
1388332_at | Ras-related C3 botulinum toxin substrate 1 | Rac1 | 4.68 | 2.25 | -0.52 | 25.71 | 4.76 | -1.43 | 4.66 | -0.05 | -0.24 | 25.24 | -1.03 | -1.18 |
1389836_a_at | Tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) | Timp3 | 4.59 | 0.51 | -0.15 | 24.06 | 1.42 | -1.11 | NC | NC | NC | NC | NC | NC |
1367563_at | secreted acidic cysteine rich glycoprotein | Sparc * | 4.58 | 1.53 | -0.18 | 23.84 | 2.89 | -1.13 | 4.43 | 1.60 | -0.07 | 21.56 | 3.03 | -1.05 |
1369947_at | cathepsin K | Ctsk * | 4.55 | 1.67 | -1.64 | 23.46 | 3.18 | -3.13 | NC | NC | NC | NC | NC | NC |
1370155_at | procollagen, type I, alpha 2 | Col1a2 * | 3.40 | 4.52 | -3.21 | 10.55 | 23.00 | -9.25 | 3.90 | -0.62 | 1.22 | 14.91 | -1.53 | 2.32 |
1367594_at | biglycan | Bgn | 4.51 | 0.13 | 0.50 | 22.78 | 1.09 | 1.42 | 3.57 | -0.29 | -0.86 | 11.91 | -1.22 | -1.81 |
1393240_at | EGF-containing fibulin-like extracellular matrix protein 2 | Efemp2 | 4.08 | 0.30 | 0.16 | 16.89 | 1.23 | 1.12 | 4.31 | 0.11 | 0.56 | 19.79 | 1.08 | 1.47 |
1368171_at | lysyl oxidase | Lox | 4.15 | 1.03 | -0.79 | 17.72 | 2.04 | -1.73 | NC | NC | NC | NC | NC | NC |
1387137_at | cartilage oligomeric matrix protein | Comp | 3.98 | 0.17 | 2.14 | 15.75 | 1.12 | 4.41 | 4.13 | -0.03 | 0.02 | 17.55 | -1.02 | 1.02 |
1387039_at | glypican 1 | Gpc1 | 4.12 | 0.06 | 0.05 | 17.44 | 1.04 | 1.04 | 3.88 | 0.60 | 0.52 | 14.76 | 1.52 | 1.44 |
1386879_at | lectin, galactose binding, soluble 3 | Lgals3 | 4.11 | 0.42 | 0.73 | 17.22 | 1.34 | 1.66 | NC | NC | NC | NC | NC | NC |
1371349_at | procollagen, type VI, alpha 1 (predicted) | Col6a1 | 3.98 | 1.94 | 0.22 | 15.78 | 3.83 | 1.17 | NC | NC | NC | NC | NC | NC |
1373615_at | frizzled-related protein | Frzb | 3.95 | 0.81 | 1.71 | 15.51 | 1.76 | 3.27 | NC | NC | NC | NC | NC | NC |
1387797_at | RAB7, member RAS oncogene family | Rab7 | 3.76 | 1.14 | -0.36 | 13.56 | 2.20 | -1.29 | NC | NC | NC | NC | NC | NC |
1367581_a_at | secreted phosphoprotein 1 | Spp1 | 3.72 | 0.41 | 1.09 | 13.20 | 1.33 | 2.12 | NC | NC | NC | NC | NC | NC |
1368187_at | glycoprotein (transmembrane) nmb | Gpnmb | 3.64 | 0.84 | -1.96 | 12.45 | 1.79 | -3.90 | NC | NC | NC | NC | NC | NC |
1386940_at | tissue inhibitor of metalloproteinase 2 | Timp2 * | 3.64 | 0.23 | -0.82 | 12.45 | 1.17 | -1.76 | NC | NC | NC | NC | NC | NC |
1367631_at | connective tissue growth factor | Ctgf † | 3.61 | 3.20 | 0.61 | 12.21 | 9.17 | 1.53 | NC | NC | NC | NC | NC | NC |
1387355_at | aggrecan 1 | Agc1 * | 3.56 | 1.34 | 0.31 | 11.83 | 2.53 | 1.24 | 3.60 | 1.58 | -0.20 | 12.13 | 2.99 | -1.15 |
1389966_at | procollagen, type VI, alpha 3 (predicted) | Col6a3 | 3.58 | 1.65 | 0.24 | 11.99 | 3.13 | 1.18 | NC | NC | NC | NC | NC | NC |
1373210_at | laminin, beta 1 (predicted) | Lamb1 | 3.56 | 1.11 | -0.44 | 11.80 | 2.16 | -1.35 | NC | NC | NC | NC | NC | NC |
1388494_at | Procollagen, type IV, alpha 2 (predicted) | Col4a2 | 2.78 | 1.88 | -2.56 | 6.88 | 3.69 | -5.90 | NC | NC | NC | NC | NC | NC |
1388459_at | procollagen, type XVIII, alpha 1 | Col18a1 | 0.53 | 0.49 | -2.79 | 1.44 | 1.40 | -6.91 | NC | NC | NC | NC | NC | NC |
1368885_at | ectonucleoside triphosphate diphosphohydrolase 1 | Entpd1 | 0.29 | 0.15 | -2.75 | 1.22 | 1.11 | -6.74 | NC | NC | NC | NC | NC | NC |
Falls within +99.9% CI | Fold Change +2 | Falls within +99.9% CI | Fold Change +2 | |||||||||||
Falls within -99.9% CI | Fold Change -2 | Falls within -99.9% CI | Fold Change -2 |
Table IX (A).
LOG2 ratio (R/L) of microarray (MC) and real time PCR (PCR) between irradiated (R) and non-irradiated (L) perichondrium
Probe ID |
Gene Title |
Gene Symbol |
7d |
11d |
16d |
R |
|||
---|---|---|---|---|---|---|---|---|---|
MC |
PCR |
MC |
PCR |
MC |
PCR |
||||
1367571_a_at | insulin-like growth factor 2 | Igf2 | 3.72 | 2.3 (0.72/0.88) | -0.03 | -0.15 (1.57/0.10) | -0.98 | -1.23 (0.42/0.49) | 0.99386 |
1370155_at | procollagen, type I, alpha 2 | Col1a2 | 1.75 | 1.1 (0.76/0.49) | -0.78 | -0.73 (0.51/0.28) | -3.42 | -3.55 (0.82/0.59) | 0.99395 |
Standard deviations of ΔCT for real time PCR (R/L) are listed in parentheses.
Table IX (B).
LOG2 ratio (R/L) of microarray (MC) and real time PCR (PCR) between irradiated (R) and non-irradiated (L) in HZ and PZ at 7 days
Probe ID |
Gene Title |
Gene Symbol |
HZ |
PZ |
||
---|---|---|---|---|---|---|
MC |
PCR* |
MC |
PCR* |
|||
1369166_at | matrix metallopeptidase 9 | Mmp9 | 6.13 | 4.88 (0.87/0.60) | ||
1370259_a_at | parathyroid homone receptor 1 | Pthr1 | 5.52 | 6.75 (1.11/1.35) | 5.34 | 6.3 (2.22/2.06) |
1367700_at | fibromodulin | Fmod | 4.69 | 3.4 (1.85/1.04) | 4.36 | 3.81 (1.73/1.01) |
1368836_a_at | aggrecan 1 | Agc1 | 3.99 | 2.99 (0.67/1.19) | 4.04 | 2.63 (0.42/0.63) |
Correlation efficient factor R | 0.7234 | 0.9966 |
Standard deviations of ΔCT for real time PCR (R/L) are listed in parentheses.
Discussion
The damaging effect of radiotherapy on growth plate chondrocytes is well documented and has been the focus of much laboratory evaluation to date. (4, 8-18) Since radiotherapy is sometimes necessary for the treatment of musculoskeletal oncology tumors in skeletally immature patients, previous work has focused on the beneficial effects of radioprotectants in selectively preventing growth plate damage. (4, 8-18) However, the chondroprotective effects of these drugs are incomplete. Recent interest in our laboratory has focused on the use of selective radiorecovery agents to stimulate growth plate return without stimulating tumor growth. Animal models suggest that the irradiated growth plate has some capacity to recover after injury. (10, 12, 16) The appearance of chondrocyte clones which repopulate the growth plate and account in large part for its functional recovery are preceded by the early upregulation of specific genes. (10, 12, 16, 17, 18) We hypothesized that the genes and pathways of greatest importance to growth plate recovery are upregulated early on during the temporal growth plate recovery process. (17, 18) In this experiment, laser microdissection was accomplished on four growth plate zones (RZ, PC, PZ and HZ) following a clinically relevant fractionated 17.5 Gy (5 × 3.5 Gy) irradiation. The purpose was to identify individual genes and pathways showing early upregulation that may play an important role in growth plate radiorecovery. Based upon the results, we can now confirm our hypotheses that (1) differential upregulation of specific gene expression exists between irradiated and nonirradiated RZ, PZ, PC and HZ chondrocytes and (2) that a number of factors potentially vital to growth plate recovery do follow a pattern of early upregulation followed by a decrease in expression.
Each zone examined in the current study had a number of pathways showing enrichment following the pattern of hypothesized importance to growth plate recovery, yet few met the strictest filters applied. Among the four zones, the majority of the clusters for the PC, PZ, and HZ fit the hypothesized pattern, whereas only half of the RZ clusters did. The PZ and HZ were the two zones with the greatest number of genes showing a 10 fold change at 7 days after initiation of fractionated irradiation, having 244 and 245 genes, respectively, meeting those criteria. These two zones also showed enrichment of the most functional pathways involved BCMSD (9 in PZ and 12 in HZ) at the strictest filter criteria (having a minimum of five transcripts). Broadening the filter to include a minimum of only two transcripts, the PZ showed 16 and the HZ showed 19 enriched pathways involved BCMSD. In using the broadened filter criteria the PC also showed four enriched pathways BCMSD. With only 18 PC genes and 23 RZ genes having passed the differential expression level filter, it is not surprising that none of the pathways involved in BCMSD had a minimum of five transcripts in either of those two zones.
There was considerable overlap between the 9 PZ and 12 HZ BCMSD pathways showing enrichment in the PZ and HZ. The 9 overlapping pathways included: 4 involved in skeletal development (skeletal development, ossification, bone remodeling and cartilage development) and 5 involved in extracellular matrix or extracellular matrix structural constituent (extracellular matrix structural constituent, proteinaceous extracellular matrix, collagen, extracellular matrix, and extracellular matrix part). Because of some overlap in GO terminology, some of the skeletal development pathways were also involved in bone remodeling and cartilage development. (Table III)
Earlier analogous work in our laboratory with post-irradiation laser microdissection utilized a more pragmatic but less clinically applicable radiation scheme of a single 17.5 Gy fraction in examining the early post-radiation growth plate response. (17, 18) In those studies, microarray analysis was performed on chondrocytes obtained by laser microdissection from the proliferative zone (PZ) and hypertrophic zone (HZ) of normal and irradiated tibia growth plates. Furthermore, pathway analysis was not as rigorous as in the current report. From the perspective of cytokines and growth factors in the earlier work, IGF2 was found to be up-regulated in the PZ and CTGF to be up-regulated in both the PZ and HZ at one week after single fraction irradiation.(17) Since this earliest time point examined occurred prior to the histomorphometric appearance of growth plate recovery previously reported in this immature animal radiation model, IGF2 and CTGF were suggested to be important to early growth plate recovery.(10, 17) By two weeks after that single 17.5 Gy fraction, a number of other growth factors and cytokines (CTGF and Pthr1 in both zones, CXCL12 and its receptor in the PZ, and IL-17b and bone morphogenetic protein 2 in the HZ) showed upregulation, suggesting a possible later role in radiorecovery.(17)
Three of the growth factor and cytokine genes previously reported to be upregulated were found to fit the hypothesized pattern of early upregulation after fractionated radiation. These genes were also involved in the 12 enriched pathways shared by the proliferative and hypertrophic zones. These include PTHr1 in both zones, CTGF in HZ, and BMP2 in HZ. While each of these genes were significantly upregulated 7 days after the initiation of the fractionation scheme, only CTGF had followed that pattern in the earlier work of single fraction irradiation, while both PTHr1 and BMP2 were elevated later in the response sequence. Interestingly, CTGF remained elevated at both timepoints in our earlier work, but while it remained meaningfully upregulated through 11 days after this fractionation scheme, it was no longer upregulated by 16 days. The other potentially important early growth factor contributor to growth plate recovery, IGF2, was not among the 34 genes following the hypothesized pattern drawn from the 12 enriched pathways. (Table VIII) Putting these findings together, two explanations seem plausible. First, IGF2 may play less of a role in recovery from the smaller fractionated radiotherapy insults while BMP2 and PTHR1, along with CTGF, may play more of a role. The alternative explanation is that a very early peak of IGF2 and CTGF was missed with the peak in CTGF persisting longer.
From the perspective of extracellular matrix (ECM) changes after irradiation, the report of Zhang et al utilized the same single 17.5 Gy fraction with laser microdissection of only the PZ and HZ in preparation for microarray, real-time PCR, and in situ hybridization. (18) In that work, both at one and two weeks after irradiation, normally expressed ECM genes and others not highly expressed in the normal growth plate showed upregulation. Conversely, metalloproteinases and cathepsins were down-regulated. Premature terminal differentiation was observed in the PZ by gene expression changes resulting in features of the normal HZ. In addition to normally expressed ECM genes (such as Ibsp, Mgp, Col1a2, Col1a1), ECM genes not highly expressed in the normal growth plate in the earlier study included several members of the small leucine-rich proteins (SLRP) and the ezrin-radixin-moesin (ERM) family. The accumulation of matrix following radiation injury to the growth plate, as previously reported in a predominately histomorphometric study, correlated well with the observed changes in ECM gene expression in the single fraction model.(10,18) Upregulation of the less commonly described growth plate genes was offered as support for their importance in the injury and repair response.(18)
Among the list of 34 genes fitting the hypothesized temporal pattern of importance and derived from the genes comprising the 12 enhanced PZ and/or HZ pathways, there were nine extracellular matrix genes that had previously been reported as being meaningfully upregulated at some point during the recovery phases after growth plate irradiation.(18) Matrix Gla protein and fibronectin followed a similar pattern as reported previously, being meaningfully upregulated at 7 days after the initiation of the fractionated scheme but then also remaining elevated throughout the time of observation in both zones. Fibromodulin also showed a similar pattern as it had following the single fraction irradiation, remaining upregulated in both zones for longer than just one week after initiating fractionated irradiation. Secreted acidic cysteine rich glycoprotein was upregulated early after irradiation in both manuscripts, but only within the HZ in the current results. Conversely, procollagen type I alpha 2 was meaningfully upregulated in both zones early after irradiation in the current manuscript but was similarly upregulated only in the PZ after single fraction irradiation. Aggrecan was upregulated (only in the HZ) in the current manuscript but not in the previously reported one. Interestingly, two proteases that had been downregulated early after irradiation by single fraction irradiation (cathepsin K and tissue inhibitor of metalloproteinase 2) were upregulated early on after the current scheme along with other proteases, including matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 3.
A number of pathways that are potential targets for manipulation of the post-radiation growth plate recovery process have been identified. Some of the genes involved in these pathways are identical to those identified as being important in this process using an earlier model. Still, many do not have a previously defined role in radiorecovery response or even the growth plate as a whole in some cases. Further work will be needed to determine the precise roles that each of these pathways has and how they may be manipulated to bring about selective radiorecovery responses.
Supplementary Material
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of Interest Notification: None
References
- 1.Butler MS, Robertson WW, Jr., Rate W, et al. Skeletal sequelae of radiation therapy for malignant childhood tumors. Clin Orthop Relat Res. 1990:235–240. [PubMed] [Google Scholar]
- 2.Goldwein JW. Effects of radiation therapy on skeletal growth in childhood. Clin Orthop Relat Res. 1991:101–107. [PubMed] [Google Scholar]
- 3.Robertson WW, Jr., Butler MS, D’Angio GJ, et al. Leg length discrepancy following irradiation for childhood tumors. J Pediatr Orthop. 1991;11:284–287. [PubMed] [Google Scholar]
- 4.Damron TA, Spadaro JA, Margulies B, et al. Dose response of amifostine in protection of growth plate function from irradiation effects. Int J Cancer. 2000;90:73–79. [PubMed] [Google Scholar]
- 5.Damron TA, Spadaro JA, Horton JA, et al. Novel radioprotectant drugs for sparing radiation-induced damage to the physis. Int J Radiat Biol. 2004;80:217–228. doi: 10.1080/09553000410001669524. [DOI] [PubMed] [Google Scholar]
- 6.Wang Y, Zhang M, Middleton FA, et al. Connective tissue growth factor and insulin-like growth factor 2 show upregulation in early growth plate radiorecovery response following irradiation. Cells Tissues Organs. 2007;186:192–203. doi: 10.1159/000105673. [DOI] [PubMed] [Google Scholar]
- 7.Zhang M, Pritchard MR, Middleton FA, et al. Microarray analysis of perichondral and reserve growth plate zones identifies differential gene expressions and signal pathways. Bone. 2008 doi: 10.1016/j.bone.2008.04.021. doi:10.1016/j.bone.2008.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tamurian RM, Damron TA, Spadaro JA. Sparing radiation-induced damage to the physis by radioprotectant drugs: laboratory analysis in a rat model. J Orthop Res. 1999;17:286–292. doi: 10.1002/jor.1100170219. [DOI] [PubMed] [Google Scholar]
- 9.Spadaro JA, Baesl MT, Conta AC, et al. Effects of irradiation on the appositional and longitudinal growth of the tibia and fibula of the rat with and without radioprotectant. J Pediatr Orthop. 2003;23:35–40. [PubMed] [Google Scholar]
- 10.Damron TA, Margulies BS, Strauss JA, et al. Sequential histomorphometric analysis of the growth plate following irradiation with and without radioprotection. J Bone Joint Surg Am. 2003;85-A:1302–1313. doi: 10.2106/00004623-200307000-00017. [DOI] [PubMed] [Google Scholar]
- 11.Margulies B, Morgan H, Allen M, et al. Transiently increased bone density after irradiation and the radioprotectant drug amifostine in a rat model. Am J Clin Oncol. 2003;26:e106–114. doi: 10.1097/01.COC.0000077934.48841.40. [DOI] [PubMed] [Google Scholar]
- 12.Damron TA, Mathur S, Horton JA, et al. Temporal changes in PTHrP, Bcl-2, Bax, caspase, TGF-beta, and FGF-2 expression following growth plate irradiation with or without radioprotectant. J Histochem Cytochem. 2004;52:157–167. doi: 10.1177/002215540405200203. [DOI] [PubMed] [Google Scholar]
- 13.Damron TA, Horton JA, Naqvi A, et al. Decreased proliferation precedes growth factor changes after physeal irradiation. Clin Orthop Relat Res. 2004:233–242. doi: 10.1097/01.blo.0000129344.28160.9d. [DOI] [PubMed] [Google Scholar]
- 14.Spadaro JA, Horton JA, Margulies BS, et al. Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone. Int J Radiat Biol. 2005;81:759–765. doi: 10.1080/09553000500495710. [DOI] [PubMed] [Google Scholar]
- 15.Damron TA, Horton JA, Naqvi A, et al. Combination radioprotectors maintain proliferation better than single agents by decreasing early parathyroid hormone-related protein changes after growth plate irradiation. Radiat Res. 2006;165:350–358. doi: 10.1667/rr3504.1. [DOI] [PubMed] [Google Scholar]
- 16.Horton JA, Margulies BS, Strauss JA, et al. Restoration of growth plate function following radiotherapy is driven by increased proliferative and synthetic activity of expansions of chondrocytic clones. J Orthop Res. 2006;24:1945–1956. doi: 10.1002/jor.20251. [DOI] [PubMed] [Google Scholar]
- 17.Margulies BS, Horton JA, Wang Y, et al. Effects of Radiation Therapy on Chondrocytes In Vitro. Calcif Tissue Int. 2006 doi: 10.1007/s00223-005-0135-3. [DOI] [PubMed] [Google Scholar]
- 18.Zhang M, Wang Y, Middleton FA, et al. Growth plate zonal microarray analysis shows upregulation of extracellular matrix genes and downregulation of metalloproteinases and cathepsins following irradiation. Calcif Tissue Int. 2007;81:26–38. doi: 10.1007/s00223-007-9025-1. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.